Ascendis Pharma A/S announced that on March 30, 2026, it closed an exercise window for outstanding warrants, resulting in an increase of share capital by nominal DKK 399,438, totaling DKK 62,376,846 with approximately USD $92.10 per share. This event is significant as it reflects changes in the company's capital structure and financial standing.